Vaccines & Disease · Dengue

Dengue Disease & Vaccine Information

Below are brief introductions to dengue disease and the dengue vaccine with links to more information. Scroll down for a list of QUICK FACTS that provide a summary overview of key facts for the disease and the vaccine.

Published May 25, 2024
The Disease

Dengue: The Disease

Dengue illness is caused by an infection with the dengue virus, a flavivirus, that is transmitted by the Aedes aegypti and the Aedes albopictus mosquitoes, two types of mosquitoes found in subtropic and tropic regions of the world.1

There are four dengue serotypes (Type 1, 2, 3, and 4), and infection with one of the dengue viruses will provide a person with long-term immunity from that specific virus. It is possible to become infected with dengue more than once since there are four distinct types of dengue viruses.2

The Vaccine

Dengue: The Vaccine

The U.S. Food and Drug Administration (FDA) has approved DENGVAXIA, a live dengue tetravalent vaccine targeting dengue serotypes 1, 2, 3, and 4 for use in children and adolescents aged six through 16 years with a laboratory confirmed history of previous dengue infection and living in dengue endemic area.3 The U.S. Center for Disease Control and Prevention (CDC) recommends DENGVAXIA vaccine for use in children aged nine through 16 years with a laboratory confirmed history of past dengue infection and who live in dengue endemic U.S. Territories and Freely Associated States.4

DENGVAXIA is not approved for individuals who have no prior history of dengue infection or where the history of previous infection is not known. Individuals with no prior history of dengue are at an increased risk of developing severe dengue infection should they receive this vaccine and become infected with the dengue virus.5

Quick Facts

Dengue at a glance

Dengue Quick Facts

  1. Dengue is an illness caused by the dengue virus, a virus that is transmitted by infected mosquitoes found in tropic and subtropic regions, including the U.S. Territories and Freely Associated States (Puerto Rico, U.S. Virgin Islands, American Samoa, the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau), the Caribbean, South and Central America, Southeast Asia, Sub-Saharan Africa, Indonesia, and Northeastern Australia.67
  2. Dengue infection can range from asymptomatic infection, to mild or severe illness. The illness generally presents as a high fever 4-7 days after infection. A red, flat rash covering the entire body often occurs 2-5 days after the fever begins. A second “measles-like” rash may also appear on the skin. Additional symptoms include nausea, vomiting, fatigue, muscle and joint pain, headache mainly behind the eyes, cough, swollen lymph nodes, nasal congestion, and sore throat. Rarely, severe dengue illness can occur, and can lead to hospitalization and even death. 89

Dengue Vaccine Quick Facts

  1. The most commonly reported adverse reactions following vaccination with DENGVAXIA included headache, injection site pain, generalized discomfort (malaise), lack of energy, and muscle pain. Additional reported adverse reactions included abdominal pain, vomiting, shortness of breath, generalized redness of the skin (erythema), hives, asthma crisis, and vertigo. Serious adverse events reported after vaccination include convulsion, acute disseminated encephalomyelitis, hives, acute asthma, and death.10
  2. Using the MedAlerts search engine, as of January 2, 2026, there have been 556 reports of dengue vaccine reactions, including 189 hospitalizations, and 269 deaths. Almost 50 percent of adverse events reported following dengue vaccine resulted in death.
References
  1. 1Morales I, Salje H, Saha S et al. Seasonal Distribution and Climatic Correlates of Dengue Disease in Dhaka, Bangladesh. Am J Trop Med Hyg. Jun 1, 2016; 94(6):1359-61.
  2. 2US Centers for Disease Control and Prevention. Clinical Presentation for Healthcare Providers. Apr. 13, 2023.
  3. 3Sanofi Pasteur. Package Insert-DENGVAXIA. U.S. Food and Drug Administration Aug. 8, 2023.
  4. 4Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Dec. 17, 2021.
  5. 5Sanofi Pasteur. Package Insert-DENGVAXIA. U.S. Food and Drug Administration Aug. 8, 2023.
  6. 6Paz-Bailey G, Adams L, Wong JM, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Dec. 17, 2021.
  7. 7World Health Organization. Dengue and severe dengue. Apr. 23, 2024.
  8. 8US Centers for Disease Control and Prevention. Symptoms of Dengue and Testing. May 14, 2024.
  9. 9NIH – National Library of Medicine MedlinePlus. Dengue fever. Dec. 4, 2022.
  10. 10Sanofi Pasteur. Package Insert-DENGVAXIA. U.S. Food and Drug Administration Aug. 8, 2023.
Select disease / vaccine

Below are brief introductions to dengue disease and the dengue vaccine with links to more information. Scroll down for a list of QUICK FACTS that provide a summary overview of key facts for the disease and the vaccine.

Dengue: The Disease

Dengue illness is caused by an infection with the dengue virus, a flavivirus, that is transmitted by the Aedes aegypti and the Aedes albopictus mosquitoes, two types of mosquitoes found in subtropic and tropic regions of the world.1

There are four dengue serotypes (Type 1, 2, 3, and 4), and infection with one of the dengue viruses will provide a person with long-term immunity from that specific virus. It is possible to become infected with dengue more than once since there are four distinct types of dengue viruses.2 Learn more about dengue…

Dengue: The Vaccine

The U.S. Food and Drug Administration (FDA) has approved DENGVAXIA, a live dengue tetravalent vaccine targeting dengue serotypes 1, 2, 3, and 4 for use in children and adolescents aged six through 16 years with a laboratory confirmed history of previous dengue infection and living in dengue endemic area.3 The U.S. Center for Disease Control and Prevention (CDC) recommends DENGVAXIA vaccine for use in children aged nine through 16 years with a laboratory confirmed history of past dengue infection and who live in dengue endemic U.S. Territories and Freely Associated States.4

DENGVAXIA is not approved for individuals who have no prior history of dengue infection or where the history of previous infection is not known. Individuals with no prior history of dengue are at an increased risk of developing severe dengue infection should they receive this vaccine and become infected with the dengue virus.5 Learn more about dengue vaccine…

Dengue & Dengue Vaccine Quick Facts

Dengue

  • Dengue is an illness caused by the dengue virus, a virus that is transmitted by infected mosquitoes found in tropic and subtropic regions, including the U.S. Territories and Freely Associated States (Puerto Rico, U.S. Virgin Islands, American Samoa, the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau), the Caribbean, South and Central America, Southeast Asia, Sub-Saharan Africa, Indonesia, and Northeastern Australia.67
  • Dengue infection can range from asymptomatic infection, to mild or severe illness. The illness generally presents as a high fever 4-7 days after infection. A red, flat rash covering the entire body often occurs 2-5 days after the fever begins. A second “measles-like” rash may also appear on the skin. Additional symptoms include nausea, vomiting, fatigue, muscle and joint pain, headache mainly behind the eyes, cough, swollen lymph nodes, nasal congestion, and sore throat. Rarely, severe dengue illness can occur, and can lead to hospitalization and even death. 8 9 Continue reading quick facts…

Dengue Vaccine

  • The most commonly reported adverse reactions following vaccination with DENGVAXIA included headache, injection site pain, generalized discomfort (malaise), lack of energy, and muscle pain. Additional reported adverse reactions included abdominal pain, vomiting, shortness of breath, generalized redness of the skin (erythema), hives, asthma crisis, and vertigo. Serious adverse events reported after vaccination include convulsion, acute disseminated encephalomyelitis, hives, acute asthma, and death.10
  • Using the MedAlerts search engine, as of January 2, 2026, there have been 556 reports of dengue vaccine reactions, including 189 hospitalizations, and 269 deaths. Almost 50 percent of adverse events reported following dengue vaccine resulted in death. Continue reading quick facts…


IMPORTANT NOTE: NVIC encourages you to become fully informed about Dengue and the Dengue vaccine by reading all sections in the Table of Contents, which contains many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.

 

References: